TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03316690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Description: Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical training
Description: Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
Study: NCT01824849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total arytenoidectomy
Description: Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial arytenoidectomy
Description: Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
Study: NCT00807599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant x 1 or x 2
Description: After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide and dexamethasone
Description: Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
Study: NCT01881230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Study: NCT04301752

Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Description: Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.

Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Description: Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.
Study: NCT01868230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Study: NCT01228292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrasate
Description: Citrasate is infused as a dialysate
Study: NCT04454541

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided nerve block for headache management
Description: The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve block for headache management
Description: The study was done to compare the efficacy of two different techniques: multifidus cervicus plan block and greater occipital nerve block in treatment of refractory cervicogenic headache using ultrasound guided.
Study: NCT02604758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Psychiatric Nursing Approach Based On The Tidal Model
Description: To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
Study: NCT04326686

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention: nuts and wholegrains with dietary advice for a blood-pressure lowering diet
Description: 30g mixed unsalted tree nuts (almonds, hazelnuts and almonds) per day; 3 portions of wholegrain foods per day (including wholegrain cereal products, wholegrain bread and wholegrain pasta); guidance for following the Dietary Approaches to Stop Hypertension (DASH) diet
Study: NCT01571869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit
Description: 1-Intervention with test product (morning, evening or snack)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- Low fat drinkable fermented dairy product without plant sterols (control)
Description: 2 - Intervention with control product (morning and/or evening)
Study: NCT02483390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial intervention
Description: e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
Study: NCT00918554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
Study: NCT01818440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D Roadmap software
Description: Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
Study: NCT01594606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-assisted intervention
Description: The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
Study: NCT01459913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study: NCT01594606

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-assisted intervention
Description: The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
Study: NCT00952003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel
Study: NCT01061580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvest SmartPReP2 BMAC System
Description: Injection of 10, 15, or 20 cc of BMAC
Study: NCT02417350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.
Study: NCT00291941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Henogen HBV vaccine
Description: 20µg, Month 0, 2 and 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FENDRIX
Description: 20 µg,Months 0, 1, 2 and 6
Study: NCT03795532

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: Shock wave lithotripsy
Study: NCT04150809

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT01379885

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique
Description: Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent participation technique
Description: The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
Study: NCT03691441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salvage neck dissection
Description: +/- Salvage neck dissection 12±2 weeks after treatment
Study: NCT01106885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Care Management (MCM)
Description: * Basic physical activity counseling~* Notify PCP and facilitate initiation of antidepressants~* Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks\*~* 1/mo monitoring in continuation phase (mos. 4-12)\*~* Report \& recommendations to PCP after each patient call~* Note: \*average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)
Study: NCT01459913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study: NCT01881230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Study: NCT01912417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise with cycle ergometer during hemodialysis
Description: Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
Study: NCT04145999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP application
Description: The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
Study: NCT01106885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: * Notify PCP~* CBT Manual~* Weekly CBT focused counseling for 12 weeks\*\*~* Monthly CBT in months 4-12\*\*~* Behavioral physical activity counseling~* Report \& recommendations to PCP after each patient call~* Note: \*\*average of 50 minutes of telephone time each
Study: NCT04145999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP application
Description: The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PRP application
Description: Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
Study: NCT02137785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Solution Vehicle
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Photodynamic Therapy Illuminator (BLU-U)
Description: 10 J/cm2 blue light delivered at 10mW/cm2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blue Light Photodynamic Therapy Illuminator (BLU-U)
Description: 10 J/cm2 blue light delivered at 10mW/cm2
Study: NCT04145999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Photobiomodulation
Description: Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
Study: NCT00942292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Contrast MRI scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Contrast MRI scan
Study: NCT03990155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNCOT+ECCO2R
Description: NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
Study: NCT04454281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Hydrochloride 0.4 MG/ML
Description: Drug will be topically applied to the corneal surface then study evaluations will ensue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone Hydrochloride 0.4 MG/ML
Description: Drug will be topically applied to the corneal surface then study evaluations will ensue.
Study: NCT01540110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Docetaxel and Cyclophosphamide
Description: 5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)
Study: NCT01874587

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adaptative radiotherapy
Description: weekly replanning
Study: NCT00400868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psycho-educational Joint protection education
Description: individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
Study: NCT03323372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate and 0.25% sodium fluoride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% potassium nitrate and 2% sodium fluoride
Study: NCT01986049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Study: NCT03668938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: Usual care consists in rehabilitation treatment delivered by a multidisciplinary team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
Study: NCT02715570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945 - single doses
Description: Safety and tolerability of single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945 - single doses
Description: Safety and tolerability of single doses